The Alternatives to PAIN Act amends Medicare Part D to make non-opioid pain management drugs more accessible and affordable to beneficiaries starting January 1, 2025. The bill waives deductibles and places qualifying non-opioid pain medications on the lowest cost-sharing tier, while also prohibiting insurance plans from requiring step therapy (forcing patients to try opioids first) or prior authorization for these drugs. Qualifying medications are defined as FDA-approved drugs for acute or postoperative pain that do not act on opioid receptors, are not controlled substances, and have no therapeutic equivalents already on the market. The legislation responds to concerns about prescription opioid misuse, which affected approximately 10 million Americans in 2019 and contributed to over 80,000 opioid overdose deaths in 2021. The bill explicitly preserves physicians' ability to prescribe any appropriate treatment, including opioids when medically necessary.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.